Overview of the Situation#

ADMA Biologics Inc. experienced a significant drop in its stock price, falling more than 9% on Tuesday afternoon. This decline followed the release of a report by short seller Culper Research, which accused the company of manipulating its revenue figures through a practice known as channel stuffing.

What is Channel Stuffing?#

Channel stuffing is a strategy where a company inflates its sales figures by sending more products to distributors than they can sell. Culper Research claims that ADMA's reported revenue growth is misleading and is primarily driven by this practice involving a related party distributor. They estimate that ADMA's actual revenue growth for 2025 was only 3%, rather than the reported 20%.

Concerns About Product Comparisons#

The report also raised concerns about ADMA's product, ASCENIV, stating that it has never undergone a head-to-head study against other treatments. ASCENIV is treated by payors as similar to standard intravenous immunoglobulins (IVIGs), which are available at lower prices. This has led to stricter requirements for insurance approvals, making it harder for patients to access the product.

Financial Discrepancies and Distributor Practices#

Culper Research highlighted discrepancies in ADMA's financial disclosures, noting an increase in the days sales outstanding (DSO) from 43 to 113 days in 2025. While ADMA reported $231 million in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), it only generated $50 million in cash from operations. Two distributors, BioCare and CuraScript, accounted for a large portion of ADMA's revenue and receivables.

Additionally, the report indicated that ADMA was allegedly offering rebates and extended payment terms to encourage distributors to stockpile ASCENIV. One distributor reportedly had payment terms extended to 120 days and was holding 4 to 6 months of inventory, compared to the usual 30 days.

Sales Data Comparison#

Culper Research provided third-party sales data showing a stark contrast between ASCENIV's actual sales and ADMA's reported revenues. For example, ASCENIV provider sales were reported at $79 million in 2023, while ADMA claimed revenues of $93 million. This discrepancy grew to $121 million by 2025, raising further questions about the company's financial practices.